In addition, the methylation frequency of MYF6 in stage I non-small cell lung cancer is obviously higher than that of non-cancerous lung disease control, which suggested that MYF6 could offer a specificity and a sensitivity in the stage I non-small cell lung cancer diagnosis [27]. This evidence concerns the gene MYF6 and non-small cell lung carcinoma.